News – Page 1143 – Endpoints News

Martin Shkreli continues college tour with stops at Harvard, UMass; Vernalis picks up $3M milestone

9 years ago

Celgene co-founder Sol Barer bags a Johns Hopkins immuno-oncology spinout in buyout

9 years ago

Agenus pockets a fast $80M in cash and hands the R&D keys over to Incyte

9 years ago

Gilead proves it's one tough contender in HIV, but don't count GSK out of the fight

9 years ago

Aviragen Therapeutics slammed again by its second trial failure in days, this time for their lead drug

9 years ago

Marathon CEO tries to call a time out on controversy as lawmakers rip into $89K deflazacort price

9 years ago

On a shopping spree, Allergan bags CoolSculpting tech in $2.5B buyout; Akebia strikes research deal with J&J

9 years ago

Sage shares get a bump from a snapshot of new PhII depression data

9 years ago

Zosano shares soar as its pivotal migraine drug patch study comes through

9 years ago

Activists slam Immunomedics’ $2B deal with Seattle Genetics in the middle of a proxy war

9 years ago

Axovant races to PhIII dementia study as nelotanserin clears an early hurdle, but questions linger

9 years ago

The scoop: Marathon’s R&D program for Duchenne MD drug likely came in at a bargain basement price

9 years ago

Tracon shares slammed by PhII bust in brain cancer study; Visterra yanks its IPO in back-to-back duds

9 years ago

Another biotech games the system, and everyone gets to pay for the fallout

9 years ago

Intercept ‘lowers the bar’ on its pivotal PhIII OCA study for NASH

9 years ago

Seattle Genetics grabs Immunomedics’ tumor drug in $2B deal, shooting for a quick OK

9 years ago

Daiichi Sankyo shutters another R&D center in an ongoing global overhaul

9 years ago

Neurocrine adds a Parkinson’s drug to its late-stage pipeline in $145M deal

9 years ago

Marathon's cheap, old steroid breezes through the FDA for Duchenne MD, and gets priced at $89K

9 years ago

Biotech voices: Allergan CEO Saunders isn’t slowing down on a brisk pace of biotech dealmaking

9 years ago

Tetraphase CEO touts troubled antibiotic’s peak sales potential; Copenhagen wants to host the EMA

9 years ago

Playing catch-up, Regeneron and Sanofi push ahead on pivotal PD-1 cancer studies

9 years ago

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII

9 years ago

After winning an early deal on XO1, the virtual biotech gang gets back together for SuperX

9 years ago

First page Previous page 1140 1141 114211431144 1145 1146 Next page Last page